9. A compound of claim 1 which is 1-(((5S,7S)-3-(5-(2-hydroxypropan-2-yl)pyrazin-2-yl)-7-methyl-2-oxo-1-oxa-3-azaspiro[4.5]decan-7-yl)methyl)-1H-benzo[d]imidazole-6-carbonitrile; or a pharmaceutically acceptable salt thereof.

10. A pharmaceutical composition comprising a compound of any one of claims 1–9 and a pharmaceutically acceptable carrier or excipient.

11. A compound of any one of claims 1-9 for use in the treatment of ~~method of treating~~ atherosclerosis, disorders related to intestinal edema, post-surgical abdominal edema, local and systemic edema, fluid retention, sepsis, hypertension, inflammation, bone related dysfunctions and congestive heart failure, pulmonary disorders, chronic obstructive pulmonary disorder, ventilator induced lung injury, high altitude induced pulmonary edema, acute respiratory distress syndrome, acute lung injury, pulmonary fibrosis, sinusitis/rhinitis, asthma, overactive bladder, pain, motor neuron disorders, genetic gain of function disorders, cardiovascular disease, renal dysfunction, osteoarthritis crohn's disease, colitis, diarrhea, intestinal irregularity (hyperreactivity/hyporeactivity), fecal incontinence, irritable bowel syndrome (IBS), constipation, intestinal pain and cramping, celiac disease, lactose intolerance, and flatulence~~, which comprises administering to a human in need thereof, a compound of any one of claims 1-9~~.

12. ~~A method~~ The compound according to claim 11 wherein the compound is to be administered orally.

13. ~~A method~~ The compound according to claim 11 wherein the compound is to be administered intravenously.

14. ~~A method~~ The compound according to claim 11 wherein the compound is to be administered by inhalation.

15. ~~A method~~ The compound according to claim 11 wherein the disease is congestive heart failure.

16. ~~A method~~ The compound according to claim 11 wherein the disease is acute lung injury.

17. Use of a compound of any one of claims 1-9 in the manufacture of a medicament for the treatment of atherosclerosis, disorders related to intestinal edema, post-surgical abdominal edema, local and systemic edema, fluid retention, sepsis, hypertension, inflammation, bone related dysfunctions and congestive heart failure, pulmonary disorders, chronic obstructive pulmonary disorder, ventilator induced lung injury, high altitude induced pulmonary edema,

acute respiratory distress syndrome, acute lung injury, pulmonary fibrosis, sinusitis/rhinitis, asthma, overactive bladder, pain, motor neuron disorders, genetic gain of function disorders, cardiovascular disease, renal dysfunction, osteoarthritis crohn's disease, colitis, diarrhea, intestinal irregularity (hyperreactivity/hyporeactivity), fecal incontinence, irritable bowel syndrome (IBS), constipation, intestinal pain and cramping, celiac disease, lactose intolerance, and flatulence.

18. The use according to claim 17 wherein the medicament is to be administered orally.

19. The use according to claim 17 wherein the medicament is to be administered intravenously.

20. The use according to claim 17 wherein the medicament is to be administered by inhalation.

21. The use according to claim 17 wherein the disease is congestive heart failure.

22. The use according to claim 17 wherein the disease is acute lung injury.